SEARCH:   Advanced

Blood, 1 August 2005, Vol. 106, No. 3, pp. 1008-1011. Prepublished online as a Blood First Edition Paper on April 19, 2005; DOI 10.1182/blood-2005-02-0607. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: 2005-02-0607v1 106/3/1008    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nishikawa, H. Articles by Gnjatic, S. Search for Related Content PubMed PubMed Citation Articles by Nishikawa, H. Articles by Gnjatic, S. Related Collections Immunobiology Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients Hiroyoshi Nishikawa, Elke Jäger, Gerd Ritter, Lloyd J. Old, and Sacha Gnjatic From the Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY; and Medizinische Klinik II, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany. A proportion of cancer patients naturally develop CD4+ T-helper type 1 (Th1) cell responses to NY-ESO-1 that correlate with anti–NY-ESO-1 serum antibodies. To address the role of T-cell regulation in the control of spontaneous tumor immunity, we analyzed NY-ESO-1–specific Th1 cell induction before or after depletion of CD4+CD25+ T cells in vitro. While Th1 cells were generated in the presence of CD25+ T cells in cancer patients seropositive for NY-ESO-1, seronegative cancer patients and healthy donors required CD25+ T-cell depletion for in vitro induction of NY-ESO-1–specific Th1 cells. In vitro, newly generated NY-ESO-1–specific Th1 cells were derived from naive precursors, whereas preexisting memory populations were detectable exclusively in patients with NY-ESO-1 antibody. Memory populations were less sensitive than naive populations to CD4+CD25+ regulatory T cells. We propose that CD4+CD25+ regulatory T cells are involved in the generation and regulation of NY-ESO-1–specific antitumor immunity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Jandus, G. Bioley, D. Dojcinovic, L. Derre, L. Baitsch, S. Wieckowski, N. Rufer, W. W. Kwok, J.-M. Tiercy, I. F. Luescher, et al. Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts Cancer Res., October 15, 2009; 69(20): 8085 - 8093. [Abstract] [Full Text] [PDF] T. Tsuji, N. K. Altorki, G. Ritter, L. J. Old, and S. Gnjatic Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination J. Immunol., October 1, 2009; 183(7): 4800 - 4808. [Abstract] [Full Text] [PDF] Y.-C. Lin, L.-Y. Chang, C.-T. Huang, H.-M. Peng, A. Dutta, T.-C. Chen, C.-T. Yeh, and C.-Y. Lin Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity J. Immunol., May 15, 2009; 182(10): 6095 - 6104. [Abstract] [Full Text] [PDF] T. Nicholaou, L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, et al. Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma Clin. Cancer Res., March 15, 2009; 15(6): 2166 - 2173. [Abstract] [Full Text] [PDF] S. Gnjatic, N. K. Altorki, D. N. Tang, S.-M. Tu, V. Kundra, G. Ritter, L. J. Old, C. J. Logothetis, and P. Sharma NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells Clin. Cancer Res., March 15, 2009; 15(6): 2130 - 2139. [Abstract] [Full Text] [PDF] C. Lehe, H. Ghebeh, A. Al-Sulaiman, G. Al Qudaihi, K. Al-Hussein, F. Almohareb, N. Chaudhri, F. Alsharif, H. Al-Zahrani, A. Tbakhi, et al. The Wilms' Tumor Antigen Is a Novel Target for Human CD4+ Regulatory T Cells: Implications for Immunotherapy Cancer Res., August 1, 2008; 68(15): 6350 - 6359. [Abstract] [Full Text] [PDF] H. Nishikawa, T. Kato, M. Hirayama, Y. Orito, E. Sato, N. Harada, S. Gnjatic, L. J. Old, and H. Shiku Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling Cancer Res., July 15, 2008; 68(14): 5948 - 5954. [Abstract] [Full Text] [PDF] N. Larmonier, J. Cantrell, C. LaCasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky, and E. Katsanis Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression J. Leukoc. Biol., April 1, 2008; 83(4): 1049 - 1059. [Abstract] [Full Text] [PDF] H. Nishikawa, T. Tsuji, E. Jager, G. Briones, G. Ritter, L. J. Old, J. E. Galan, H. Shiku, and S. Gnjatic Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector Blood, February 1, 2008; 111(3): 1404 - 1412. [Abstract] [Full Text] [PDF] S. Hao, Y. Liu, J. Yuan, X. Zhang, T. He, X. Wu, Y. Wei, D. Sun, and J. Xiang Novel Exosome-Targeted CD4+ T Cell Vaccine Counteracting CD4+25+ Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory CD8+ CTL Responses J. Immunol., September 1, 2007; 179(5): 2731 - 2740. [Abstract] [Full Text] [PDF] E. Yakirevich and M. B. Resnick Regulatory T Lymphocytes: Pivotal Components of the Host Antitumor Response J. Clin. Oncol., June 20, 2007; 25(18): 2506 - 2508. [Full Text] [PDF] G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF] A. M. Asemissen, U. Keilholz, S. Tenzer, M. Muller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, et al. Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 Clin. Cancer Res., December 15, 2006; 12(24): 7476 - 7482. [Abstract] [Full Text] [PDF] M. Beyer and J. L. Schultze Regulatory T cells in cancer Blood, August 1, 2006; 108(3): 804 - 811. [Abstract] [Full Text] [PDF] M. Condomines, P. Quittet, Z.-Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J.-F. Schved, et al. Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor. J. Immunol., June 1, 2006; 176(11): 6631 - 6639. [Abstract] [Full Text] [PDF] H. Nishikawa, F. Qian, T. Tsuji, G. Ritter, L. J. Old, S. Gnjatic, and K. Odunsi Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination J. Immunol., May 15, 2006; 176(10): 6340 - 6346. [Abstract] [Full Text] [PDF] C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity. Cancer Res., April 15, 2006; 66(8): 4450 - 4460. [Abstract] [Full Text] [PDF] D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius, and C. Marth The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer Clin. Cancer Res., December 1, 2005; 11(23): 8326 - 8331. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020